Parameters of Tissue Doppler Echocardiography. by Mina Farshidgohar (20308230)

“…</p><p>Results</p><p>Out of 50 patients, two showed a decrease in left ventricular ejection fraction (LVEF) below the normal range (<55%) one month post-treatment, along with significant increases in Troponin I levels. …”

Supplementary file 1_Comparison of morrow procedure and transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy: a systematic review and... by Maxat Zhakayev (22445197)

“…</p>Results<p>Both procedures achieved substantial and comparable reductions in LVOTG, with no significant between-group difference (p = 0.75). Functional status improved in both cohorts; younger age and higher study quality were independently associated with greater improvement in NYHA class (p < 0.05). …”

Table 1_Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.docx by Hiroo Fukada (5154824)

“…The dapagliflozin group showed additional benefits, with significant decreases in BMI and HbA1c, γ-GT, ferritin, LDL cholesterol, and body fat levels, indicating improved glycemic control and lipid profile. …”

Baseline characteristics of patients. by Su Hwan Park (15158181)

“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table 1_Long-term multicomponent exercise enhances functional mobility in early-stage Parkinson’s disease: a 48-month retrospective cohort study.docx by Marcos Moura (22671914)

“…Minimal detectable change (MDC), effect sizes, and linear regressions were computed.</p>Results<p>After 48 months, TUG time decreased by −3.8 s (95% CI: −5.0 to −2.6; p < 0.001; dz = −1.12) and 6MWT distance increased by +88.8 m (95% CI: 45.1 to 133.0; p < 0.001; dz = 0.72), both exceeding MDC thresholds. …”

Table 1_Associations between systemic inflammatory indices and the risk of renal function decline in patients with type 2 diabetes mellitus: a retrospective cohort study.docx by Zhi Shang (4849129)

“…The RCS analysis suggested a non-linear association of systemic inflammatory indices with the risk of renal function decline (P for nonlinear < 0.001). …”

Data Sheet 1_The effects of acupoint catgut embedding therapy on anthropometric parameters and endocrine function in obese women: a systematic review and meta-analysis.pdf by Shuangqiu Li (8083634)

“…Hormonal changes included decreased LH and FSH and increased E2.</p>Conclusion<p>Our meta-analysis demonstrates that ACET significantly improves anthropometric parameters and endocrine function in obese women, though it does not significantly impact lipid metabolism or insulin resistance. …”

Dataset study -Impact of Technical Standardization on Pneumothorax and Chest Tube Insertion Rates: A Retrospective Learning Curve Analysis of CT-Guided Lung Biopsies by Rosa Alba Pugliesi (20766383)

Table 2_Following changes in brain structure and function with multimodal MRI in a year-long prospective study on the development of Type 2 diabetes.xlsx by Yingjie Wang (354135)

“…There were no significant changes in cognitive or motor behavior over the yearlong study but there was a significant increase in sensitivity to peripheral pain in diet fed rats. …”

Table 1_Following changes in brain structure and function with multimodal MRI in a year-long prospective study on the development of Type 2 diabetes.xlsx by Yingjie Wang (354135)

“…There were no significant changes in cognitive or motor behavior over the yearlong study but there was a significant increase in sensitivity to peripheral pain in diet fed rats. …”

Supplementary Material for: Real-World Insights into Avatrombopag’s Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central a... by figshare admin karger (2628495)

“…The primary endpoint was achieving a platelet response at Week 8. Results: AVA treatment resulted in a 68.3% platelet response rate by Week 8, with a significant increase in median platelet counts. …”

Image 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 5_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 6_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”